Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications
Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 01, 2024
Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non-Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02.
Journal: The Journal of molecular diagnostics : JMD
Published: July 01, 2024
Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer.
Journal: British journal of cancer
Published: December 27, 2023
Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes.
Journal: JCO precision oncology
Published: September 28, 2023
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
Journal: Oncology (Williston Park, N.Y.)
Published: April 27, 2023
Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.
Journal: The Journal of molecular diagnostics : JMD
Published: December 21, 2022
Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer.
Journal: British journal of cancer
Published: October 14, 2022
Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy.
Journal: Therapeutic advances in medical oncology
Published: May 24, 2022
Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer.
Journal: JCO precision oncology
Published: May 11, 2022
Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab.
Journal: The Journal of molecular diagnostics : JMD
Published: October 20, 2021
Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.
Journal: Cancer medicine
Published: October 04, 2021
Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer.
Journal: ESMO open
Published: August 25, 2021
Last Updated: 09/26/2026